JP2004513079A5 - - Google Patents

Download PDF

Info

Publication number
JP2004513079A5
JP2004513079A5 JP2002518242A JP2002518242A JP2004513079A5 JP 2004513079 A5 JP2004513079 A5 JP 2004513079A5 JP 2002518242 A JP2002518242 A JP 2002518242A JP 2002518242 A JP2002518242 A JP 2002518242A JP 2004513079 A5 JP2004513079 A5 JP 2004513079A5
Authority
JP
Japan
Prior art keywords
peptide
trp
amino acid
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002518242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004513079A (ja
JP4860096B2 (ja
Filing date
Publication date
Priority claimed from IL137820A external-priority patent/IL137820A/en
Application filed filed Critical
Publication of JP2004513079A publication Critical patent/JP2004513079A/ja
Publication of JP2004513079A5 publication Critical patent/JP2004513079A5/ja
Application granted granted Critical
Publication of JP4860096B2 publication Critical patent/JP4860096B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002518242A 2000-08-10 2001-08-06 鎮痛性ペプチドを含んでなる薬剤組成物 Expired - Lifetime JP4860096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL137820A IL137820A (en) 2000-08-10 2000-08-10 Pharmaceutical composition for topical administration comprising an analgesic peptide
IL137820 2000-08-10
PCT/IL2001/000724 WO2002012269A2 (en) 2000-08-10 2001-08-06 Pharmaceutical composition comprising an analgesic peptide

Publications (3)

Publication Number Publication Date
JP2004513079A JP2004513079A (ja) 2004-04-30
JP2004513079A5 true JP2004513079A5 (cg-RX-API-DMAC7.html) 2008-11-13
JP4860096B2 JP4860096B2 (ja) 2012-01-25

Family

ID=11074512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002518242A Expired - Lifetime JP4860096B2 (ja) 2000-08-10 2001-08-06 鎮痛性ペプチドを含んでなる薬剤組成物

Country Status (12)

Country Link
US (1) US7220725B2 (cg-RX-API-DMAC7.html)
EP (1) EP1309613B1 (cg-RX-API-DMAC7.html)
JP (1) JP4860096B2 (cg-RX-API-DMAC7.html)
CN (2) CN102160890B (cg-RX-API-DMAC7.html)
AT (1) ATE392428T1 (cg-RX-API-DMAC7.html)
AU (2) AU8005201A (cg-RX-API-DMAC7.html)
CA (1) CA2418793C (cg-RX-API-DMAC7.html)
DE (1) DE60133654T2 (cg-RX-API-DMAC7.html)
DK (1) DK1309613T3 (cg-RX-API-DMAC7.html)
ES (1) ES2305096T3 (cg-RX-API-DMAC7.html)
IL (1) IL137820A (cg-RX-API-DMAC7.html)
WO (1) WO2002012269A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
US8252754B2 (en) * 2005-03-21 2012-08-28 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway
US20100190723A1 (en) * 2007-03-23 2010-07-29 Hiroo Sanada Preventive or therapeutic composition for liver disease
US20110183925A1 (en) * 2008-09-22 2011-07-28 Nisshin Pharma Inc. Anti-inflammatory peptide
CN102686221B (zh) 2009-07-27 2018-04-17 诺西赛普塔有限责任公司 治疗疼痛的方法
FR2948809B1 (fr) * 2009-07-31 2012-08-17 St Microelectronics Rousset Amplificateur de lecture faible puissance auto-minute
ES2598829T3 (es) * 2011-03-28 2017-01-30 S.I.S. Shulov Innovative Science Ltd. Procedimiento de tratamiento de trastornos cutáneos
CN107847552B (zh) 2015-01-07 2022-07-01 三叉神经股份公司 含镁的催产素制剂和使用方法
EP4541348A3 (en) 2016-04-12 2025-06-04 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
RU2669386C1 (ru) * 2017-08-11 2018-10-11 Закрытое акционерное общество "Институт экспериментальной фармакологии" Состав и способ получения анальгетического средства пептидной структуры
KR20200138326A (ko) 2018-03-29 2020-12-09 에스.아이.에스. 슐로브 이노베이티브 사이언스 리미티드 염증성 시토카인을 억제하기 위한 약제학적 조성물
US11644463B2 (en) 2019-08-30 2023-05-09 Euroimmun Medizinische Labordiagnostika Ag Detection of an autoantibody
AU2020356605A1 (en) * 2019-09-26 2022-04-14 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
WO2021059267A1 (en) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Compositions and methods for treating degenerative, age-related and trauma-induced disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491541A (en) * 1982-11-10 1985-01-01 Farmitalia Carlo Erba Peptides
IT1172391B (it) * 1983-12-23 1987-06-18 Polifarma Spa Composti tirpeptidici contenenti acido piroglutaminico e triptofano,procedimentio di produzione ed applicazioni terapeutiche
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
IT1242002B (it) * 1990-10-03 1994-02-02 Polifarma Spa Composti con attivita' farmacologica antiipertensiva, analgesica, immunomodulante e antiinfiammatoria, che presentano nella molecola una sequenza di tre radicali, essendo alfa-amminoacido quello centrale
EP0668770A1 (en) 1991-04-24 1995-08-30 Warner-Lambert Company $g(a)-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY
AUPM489194A0 (en) * 1994-04-07 1994-04-28 Luminis Pty Limited Peptides
RU2107691C1 (ru) * 1995-03-02 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AU3136897A (en) * 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
IL123001A (en) * 1998-01-20 1998-12-06 Shulov Inst For Venom Research Analgesic fraction from snake March and pharmacy preparations containing it
CA2341810A1 (en) * 1998-08-28 2000-03-09 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide

Similar Documents

Publication Publication Date Title
JP2004513079A5 (cg-RX-API-DMAC7.html)
KR970015598A (ko) 환상 결합 억제제
RU96118225A (ru) Циклопептиды, способ их получения, содержащая их фармацевтическая композиция, способ ее получения, способ борьбы с заболеваниями, способ получения иммобилизированных лигандов, способ очистки интегринов
JP2004536077A5 (cg-RX-API-DMAC7.html)
WO2002048183A3 (en) Compositions of peptide crystals
ID21956A (id) Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
JPH06501461A (ja) キニノゲナーゼ阻害剤
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
JP2002530430A (ja) C型肝炎ウイルスns3プロテアーゼ阻害用の医薬組成物
CA2418793A1 (en) Pharmaceutical composition comprising an analgesic peptide
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
DK0573538T3 (da) Peptider til behandling
EP0317573B1 (en) Antipyretic and anti-inflammatory peptides
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
CA2419423A1 (en) Conjugates of peptides and peptide mimetics having integrin inhibitor properties
KR920701244A (ko) 심실 펩티드 유도체
JPH09165400A (ja) 新規ペプチド
AU718320B2 (en) Peptide derivatives
AU718192B2 (en) Peptide derivatives
JP2003501109A5 (cg-RX-API-DMAC7.html)
WO1997049724A1 (fr) Depsipeptides cycliques et medicaments contenant ces composes comme ingredient actif
JPH09124692A5 (cg-RX-API-DMAC7.html)
WO2002062373A3 (en) Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
AU2002228260B2 (en) Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients